Lipid nanoparticles (LNPs) are widely used vehicles for mRNA-based therapeutics and vaccines. However, ionizable lipids used in LNPs can be susceptible to N-oxide impurities that can cause functional loss of the mRNA cargo.
Biopharma
Biologics characterization pose many challenges due to the diversity of the biomolecules. Learn about the many powerful tools that allow researchers to fully characterize and quantify their biologic drugs, using mass spectrometry and capillary electrophoresis instrumentation.
Adducts and N-oxides: understanding lipid nanoparticles (LNPs) for better mRNA drugs
Lipid nanoparticles (LNPs) are widely used vehicles for messenger RNA (mRNA)-based therapeutics and vaccines. However, ionizable lipids used in LNPs can be susceptible to N-oxide impurities that can cause functional loss of the mRNA cargo.
The costly consequences of unplanned downtime
Unplanned downtime is a formidable adversary that businesses across various industries strive to minimize. Defined as the unexpected interruption of regular operations, unplanned downtime can wreak havoc on productivity, profitability and customer satisfaction. In this article, we delve into the causes of unplanned downtime, its far-reaching consequences and strategies to mitigate its impact.
Beyond mRNA: how advances in analytical techniques are enabling a revolution in the RNA drug landscape
Currently, there are 3 main types of in vitro transcribed (IVT) RNA drugs. Two of these—conventional messenger RNA (mRNA) and base-modified mRNA (bmRNA), which incorporates chemically modified nucleotides—are non-replicating. The third type is self-replicating RNA (srRNA), which is based on an engineered viral genome but devoid of viral structural protein genes. Its self-replicating ability makes srRNA a promising tool for new therapeutic drugs.
Changing the game of drug development with the Intabio ZT system
What better to learn how a new technology like icIEF-UV/MS is advancing drug development than hearing from the labs that are using it?
The whys behind the dos and don’ts of oligonucleotide analysis
We know that LC-MS oligonucleotide analysis can have its share of challenges—challenges with sensitivity, challenges with adduct formation and challenges with data analysis, to name just a few. That’s why this blog takes a closer look at the dos and don’ts of this type of analysis and explores some keys to success. It also explains why following these simple rules can vastly improve your oligonucleotide characterization and quantitation efficiency and success.
Top 7 Echo® MS system customer questions—answered
You asked, we answered! With analysis speeds of at least 1 sample per second, the Echo® MS system has created a buzz in the industry. This is up to 50x faster than conventional LC-MS/MS. This revolutionary tool for drug discovery and development has led to...
Handle with care: Ensuring LNP lipid quality for better genetic medicines
Lipid nanoparticles (LNPs) are widely used vehicles for oligonucleotide-based therapeutics and vaccines. However, LNPs can be susceptible to N-oxide-based impurities that can cause messenger RNA (mRNA) to lose function.
New features in OneOmics suite
I just wanted to thank the readers here, both the OneOmics suite users who’ve shared their time and watched OneOmics grow, and for all the talented developers and scientists who’ve made OneOmics suite what it is today.
Discover high-throughput LNP-mRNA integrity profiling
Lipid-based nanoparticles (LNPs) are effective non-viral vectors for delivering messenger RNA (mRNA) products, most notably used for production of vaccines against the recent SARS-CoV-2 pandemic.